MA54856A - Monohydrate de chlorhydrate de rogaratinib et états solides associés - Google Patents

Monohydrate de chlorhydrate de rogaratinib et états solides associés

Info

Publication number
MA54856A
MA54856A MA054856A MA54856A MA54856A MA 54856 A MA54856 A MA 54856A MA 054856 A MA054856 A MA 054856A MA 54856 A MA54856 A MA 54856A MA 54856 A MA54856 A MA 54856A
Authority
MA
Morocco
Prior art keywords
rogaratinib
hydrochloride monohydrate
solid states
associated solid
states
Prior art date
Application number
MA054856A
Other languages
English (en)
Inventor
Jörg Gries
Claus-Christian Häselhoff
Kai Lovis
Johannes Platzek
Original Assignee
Bayer Pharma AG
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ag filed Critical Bayer Pharma AG
Publication of MA54856A publication Critical patent/MA54856A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
MA054856A 2019-01-31 2020-01-27 Monohydrate de chlorhydrate de rogaratinib et états solides associés MA54856A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19154781 2019-01-31

Publications (1)

Publication Number Publication Date
MA54856A true MA54856A (fr) 2022-05-04

Family

ID=65276007

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054856A MA54856A (fr) 2019-01-31 2020-01-27 Monohydrate de chlorhydrate de rogaratinib et états solides associés

Country Status (21)

Country Link
US (1) US20220098201A1 (fr)
EP (1) EP3917929A1 (fr)
JP (1) JP2022519081A (fr)
KR (1) KR20210119994A (fr)
CN (1) CN113382997A (fr)
AU (1) AU2020214188A1 (fr)
BR (1) BR112021012876A2 (fr)
CA (1) CA3128073A1 (fr)
CL (1) CL2021001977A1 (fr)
CO (1) CO2021009660A2 (fr)
DO (1) DOP2021000162A (fr)
EA (1) EA202192133A1 (fr)
EC (1) ECSP21056314A (fr)
GE (1) GEP20237531B (fr)
IL (1) IL284927A (fr)
JO (1) JOP20210204A1 (fr)
MA (1) MA54856A (fr)
MX (1) MX2021009173A (fr)
SG (1) SG11202107919YA (fr)
TW (1) TW202035413A (fr)
WO (1) WO2020156982A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2978830A1 (fr) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Combinaisons contenant des 2,3-dihydroimidazo[1,2-c]quinazoline substituees
CN113720956B (zh) * 2021-09-08 2022-03-29 广州国标检验检测有限公司 一种气质联用检测药物中硫酸酯的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0618622A2 (pt) * 2005-11-17 2011-09-06 Osi Pharm Inc composto, composição, e, uso de um composto
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
CA2635231C (fr) * 2005-12-29 2014-07-15 Abbott Laboratories Inhibiteurs de proteines kinases
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos

Also Published As

Publication number Publication date
SG11202107919YA (en) 2021-08-30
EP3917929A1 (fr) 2021-12-08
WO2020156982A1 (fr) 2020-08-06
CN113382997A (zh) 2021-09-10
MX2021009173A (es) 2021-09-10
IL284927A (en) 2021-09-30
EA202192133A1 (ru) 2022-02-09
CL2021001977A1 (es) 2022-02-25
JP2022519081A (ja) 2022-03-18
CA3128073A1 (fr) 2020-08-06
TW202035413A (zh) 2020-10-01
ECSP21056314A (es) 2021-08-31
AU2020214188A1 (en) 2021-07-15
US20220098201A1 (en) 2022-03-31
CO2021009660A2 (es) 2021-08-09
GEP20237531B (en) 2023-08-25
DOP2021000162A (es) 2021-09-15
BR112021012876A2 (pt) 2021-09-08
JOP20210204A1 (ar) 2023-01-30
KR20210119994A (ko) 2021-10-06

Similar Documents

Publication Publication Date Title
DK3565550T3 (da) Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan
IL266611B (en) Converted n-(3-fluorophenyl)-pyrrolidine substances, and their pharmaceutical compounds
MA45937A (fr) Inhibiteurs d'amino pyrimidine ssao
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
IL277794A (en) ATF6 inhibitors and uses thereof
DK3514153T3 (da) Pyrimidinforbindelse og farmaceutisk anvendelse deraf
DK3412660T3 (da) Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
DK3255042T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme
DK3709978T3 (da) Farmaceutisk oral formulering omfattende bakterier
DK3560925T3 (da) Hidtil ukendt forbindelse og farmaceutisk acceptabelt salt deraf
MA49837A (fr) Compositions pharmaceutiques
MA54856A (fr) Monohydrate de chlorhydrate de rogaratinib et états solides associés
DK3911304T3 (da) Tabletformuleringer med modificeret frigivelse indeholdende phosphodiesterase-hæmmere
IL281357B (en) cd73 inhibitors and their pharmaceutical uses
SG11202101451QA (en) Novel heterocyclic amine derivative and pharmaceutical composition comprising same
IL279441A (en) History of N-converted tetrahydrothinopyridines and their uses
IL276323A (en) 4-Methyldihydropyrimidinone compounds and their pharmaceutical use
MA55015A (fr) Formulations pharmaceutiques
IL279877A (en) Ibusidanib forms and pharmaceutical preparations
ES2913376R1 (es) Compuestos de curcumina y aminoacidos basicos
IL276783A (en) The composition and pharmaceutical compound containing it
MA42552A (fr) Compositions pharmaceutiques de flurbiprofène et de tramadol
GB202204420D0 (en) Crypto-erasure via internal and/or external action
DK3908321T3 (da) Farmaceutisk sammensætning
MA52306A (fr) Agents préventifs et thérapeutiques de la sarcopénie